Next-Generation Toxicology in Pharma & Biotech

Next-Generation Toxicology in Pharma & Biotech is a comprehensive two-day training course scheduled for 21–22 October 2026 in Basel, Switzerland, and available via online live stream. The course is designed for professionals working in pharmaceutical, biotechnology, biologics, preclinical development, toxicology, regulatory affairs, pharmacology, and drug safety. Led by industry experts Dr. Pelin Candarlioglu, Founder and Director of 3D and 3Rs Ltd, and Richard Knight, PhD, ERT, Co-founder of ApconiX and an experienced drug safety specialist, the program provides a practical understanding of modern toxicology and safety assessment. Participants will explore regulatory toxicology requirements, investigative toxicology frameworks, New Approach Methodologies (NAMs), Microphysiological Systems (MPS), integrated testing strategies (IATA), AI applications in toxicology, data quality, reproducibility, and human-relevant models. The training features interactive discussions, hands-on case studies, group exercises, and real-world examples that demonstrate how innovative technologies can support better decision-making throughout drug development. Attendees will gain actionable knowledge on evaluating toxicological risks, improving regulatory confidence, and implementing next-generation safety assessment strategies in pharmaceutical and biotech research.

Toxicology, Drug Safety, Pharmaceutical Development, Biotechnology, Regulatory Affairs, Preclinical Research, Life Sciences.